Gemifloxacin is a novel quinolone with excellent activity against Gram-positive and some Gram-negative pathogens. Its activity was tested against 150 Neisseria gonorrhoeae strains, including 50 ciprofloxacin-resistant isolates, using reference agar dilution and Etest methods. 
Introduction
Antimicrobial-resistant gonococcal infection continues to be a serious and increasing problem worldwide. Initially, penicillin and tetracycline were the first-line therapy against Neisseria gonorrhoeae, but in the last three decades widespread and increasingly prevalent infections with penicillinase-producing N. gonorrhoeae (PPNG) and tetracycline-resistant N. gonorrhoeae have been documented. [1] [2] [3] [4] [5] Single-dose oral ciprofloxacin and ofloxacin have been very effective but ciprofloxacin-resistant gonococci have emerged; [6] [7] [8] the prevalence of these strains appears to be increasing worldwide. 9, 10 Moreover, the MICs of ceftriaxone and ciprofloxacin for some PPNG strains are higher than those for non-PPNG strains, 5 a recent WHO report on gonococcal surveillance during 1992-4 found that the degree of quinolone resistance had increased and that such strains had become widespread. 1 Simultaneously, a USA study showed a remarkable increase in the incidence of gonococci with reduced susceptibility to ciprofloxacin. 10 Elevated ciprofloxacin MICs have been associated with mutations of the gyrA and parC genes, 11 and veryhigh-level ciprofloxacin resistance (MICs 8-64 mg/L) is associated with double mutations in the parC gene. 12 These multiple mutations may also reduce the organism's susceptibility to newer, extended-spectrum quinolones. In other genera, quinolone resistance is also influenced by mutations in gyrB and parE and by efflux.
Gemifloxacin (SB-265805) is a novel quinolone that is more potent in vitro against a wide variety of pathogens than other currently available quinolones. [13] [14] [15] [16] Some earlier reports, studying a limited number of gonococci and no ciprofloxacin-resistant isolates, have shown gemifloxacin to be highly potent.
14 However, if gemifloxacin were to be used as a treatment for gonorrhoea, a larger number of organisms, including quinolone-resistant strains to assess the possibility of clinical cross-resistance, would need to be studied.
This study was initiated to confirm the potency of gemifloxacin against 150 gonococcal isolates, 33.3% of which had elevated ciprofloxacin MICs. The Etest results were compared with the NCCLS agar dilution method 17 in order to validate the Etest for routine clinical laboratory use.
Materials and methods

Antimicrobial agents and media
Gemifloxacin was supplied by SmithKline Beecham Pharmaceuticals (Philadelphia, PA, USA). All comparator drugs were obtained from their respective manufacturers. Antimicrobial solutions for agar MIC tests were prepared according to the manufacturers' instructions and stored in aliquots at -70°C until used. Gemifloxacin solution was made freshly on each day of testing. Gemifloxacin Etest strips were manufactured by AB Biodisk (Solna, Sweden). Plates for Etest, GC agar tubes for agar dilution testing and the NCCLS-defined supplement without cysteine were obtained from PML Microbiologicals (Wilsonville, OR, USA).
Bacterial strains
One hundred and fifty strains of N. gonorrhoeae were used in this investigation, including recent and reference stock clinical isolates. Of these gonococci, 100 were ciprofloxacin-susceptible (zone diameter у41 mm, MIC р0.06 mg/L) recent clinical isolates from University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
18 These ciprofloxacin-susceptible strains were further categorized based on their susceptibility to penicillin: 19 were penicillinsusceptible (MIC р0.06 mg/L), 25 were moderately susceptible or intermediate (MIC 0.12-1 mg/L) and 29 were penicillin-resistant (MIC у 2 mg/L) as a result of altered penicillin-binding protein targets. Twenty-seven other strains were resistant to penicillin by virtue of -lactamase production.
The other 50 N. gonorrhoeae strains were categorized as ciprofloxacin-resistant and demonstrated two levels of reduced susceptibility: 43 strains had 'low-level' resistance (MIC 0.12-0.25 mg/L) and seven had 'high-level' resistance (MIC 0.5-8 mg/L). The ciprofloxacin-resistant strains were obtained from diverse locations (27 strains from Japan, 17 from the USA and six from The Netherlands). 11, 19, 20 The isolates from Japan have previously been characterized for their gyrA and parC mutations by PCR sequencing analysis (16 strains with a gyrA mutation and 11 strains with gyrA ϩ parC substitutions). Susceptibility testing N. gonorrhoeae isolates were grown on chocolate agar plates and stored at -70°C until processed. Fresh overnight subcultures were used for susceptibility testing. For the 100 ciprofloxacin-susceptible isolates, an Etest strip containing gemifloxacin was tested, in addition to the reference agar dilution MIC test with gemifloxacin and ciprofloxacin. The ciprofloxacin non-susceptible or -resistant isolates were tested against an Etest strip and reference agar dilution test with gemifloxacin and other comparator drugs (ciprofloxacin, trovafloxacin, grepafloxacin, moxifloxacin, amoxycillin, penicillin and azithromycin). All tests were performed using NCCLS methods. 21 The quality control strain N. gonorrhoeae ATCC 49226 repeatedly produced a narrow range of values (MIC 0.004 or 0.008 mg/L), but all were within the subsequently established ranges.
17
N. gonorrhoeae
ATCC 49226, Escherichia coli ATCC 25922, Enterococcus faecalis ATCC 29212 and Staphylococcus aureus ATCC 29213 were used as quality control strains. Except for N. gonorrhoeae, preliminary quality control ranges for gemifloxacin were used for all tests and results remained within the proposed limits.
Statistical methods
The MIC results for all isolates by Etest and agar dilution methods were compared by regression analysis. Essential agreement between Etest and reference agar MIC was defined as results within ±1 log 2 dilution MIC after rounding the Etest MIC to the next appropriate two-fold dilution value.
Results
Activity of gemifloxacin against N. gonorrhoeae
The MICs of gemifloxacin for 150 strains of N. gonorrhoeae are presented in Table I . Gemifloxacin was highly active against ciprofloxacin-susceptible strains but was 16-to 32-fold less potent against ciprofloxacin-resistant isolates (MIC 90 0.12 mg/L; Table II ). The highest gemifloxacin MIC Among ciprofloxacin-susceptible strains, the levels of penicillin resistance and -lactamase production generally did not influence quinolone susceptibility. However, the high-level penicillin-resistant subgroup with chromosomally mediated resistance had a slightly higher gemifloxacin MIC than other strains (two-fold increase, data not shown). Among the ciprofloxacin-resistant strains, those with mutations in gyrA only, had ciprofloxacin and gemifloxacin MIC ranges of 0.12-1 and 0.03-0.12 mg/L, respectively. The gonococci with mutations in both gyrA and parC had eight-fold higher MICs (ranges 0.25-8 and 0.06-8 mg/L, respectively) for each quinolone. Only one strain had a gemifloxacin MIC of Ͼ0.25 mg/L. Three of these strains had two amino acid substitutions in GyrA (Ser91ǞPhe, Asp95ǞAsn or ǞGly) and a single mutation in ParC (Ser88ǞPhe or Glu91ǞGly) which produced gemifloxacin MICs of 0.06, 0.06 and 1 mg/L, respectively. The ciprofloxacin MICs for these three strains were 1-8 mg/L. Gemifloxacin was consistently equally or more potent than penicillins and amoxycillin (MIC 90 2.0 mg/L) and azithromycin (MIC 90 0.12 mg/L; Table II) . Table I shows the MIC results from the Etest compared with those obtained from the reference agar dilution method.
Intermethod comparisons
17 A trend towards a slightly lower MIC with the Etest is evident. The correlation coefficient (r) was 0.96 and the regression equation y ϭ 0.66 ϩ 0.95x. There was 98.7% essential agreement (Ϯ1 log 2 dilution) between the two methods, but 50.7% of the Etest MICs were half those determined by the reference agar dilution test.
Discussion
In this study, gemifloxacin was very active against N. gonorrhoeae, particularly those strains resistant to ciprofloxacin (MIC 90 0.12 mg/L); it was more potent than all other quinolones tested. This confirms earlier reports. 13, 14 This high potency may support the use of gemifloxacin in the treatment of gonococcal infections resistant to older quinolones and may reflect its greater affinity for mutant DNA gyrase/topoisomerase targets.
The proposed gonococcal breakpoint criterion for susceptibility to gemifloxacin (р0.25 mg/L) appears conservative and is consistent with those used for similarly potent drugs in the same class, such as trovafloxacin and gatifloxacin. 19, 20 The trovafloxacin interpretive criteria only list susceptible breakpoints, pending information from the clinical responses of strains having trovafloxacin MICs Ͼ 0.25 mg/L. 18 This practice would also seem prudent for gemifloxacin, although strains with MICs у 1 mg/L would be unlikely to be treated successfully since the reported gemifloxacin plasma C max is 1.3 mg/L with a plasma AUC of 8.3-8.5 mg·L/mL (SmithKline Beecham, data on file). 18, 22 This study also validated the Etest, an alternative reference-quality MIC test, for routine clinical laboratory use. These results confirm earlier work using the Etest for gonococci 23 and for gemifloxacin, 24 and indicate that the Etest appears to be an acceptable and accurate alternative to the agar dilution test for determining the susceptibility of gonococci to gemifloxacin.
These proposals await the correlations of the MICs for clinical strains with the clinical outcomes in patients with gonorrhoea treated with single-dose gemifloxacin. 
